Drugs that fail in late stage clinical trials: Clinical Pharmacology Can Help

Current trends in pronounced late-stage attrition rates of promising drug candidates are a pressing concern for patients, providers, and other stakeholders across the health care system. A recent commentary in the journal Clinical Pharmacology and Therapeutics, co-authored by Mark McClellan, Greg Daniel, Morgan Romine and collaborators, describes six areas in which clinical pharmacology methods and frameworks can help ameliorate these trends in late-stage attrition and increase the efficiency of drug development and evaluation. These recommendations are based, in part, on previous stakeholder engagement and input, as well as a previously published white paper.  Read the commentary.